NCT03522662 is a Phase 2 clinical trial of GSK1070806 in Behcet's Disease, sponsored by Cambridge University Hospitals NHS Foundation Trust.

Who is sponsoring NCT03522662?

NCT03522662 is sponsored by Cambridge University Hospitals NHS Foundation Trust.

What drugs are being tested in NCT03522662?

Interventions in NCT03522662: GSK1070806.

What condition does NCT03522662 study?

NCT03522662 studies Behcet's Disease.

Is NCT03522662 still recruiting?

NCT03522662 is currently status unknown. Last updated 11 May 2018.

Last reviewed 2018-05-11 · How we verify

NCT03522662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti IL-18 (GSK1070806) in Behcet's Disease

Status unknown Phase 2 Last updated 11 May 2018

What this trial tests

Phase 2 trial testing GSK1070806 in Behcet's Disease in 12 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
1 April 2020

1 April 2020

Quick facts

Lead sponsor	Cambridge University Hospitals NHS Foundation Trust
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 August 2018
Primary completion	1 April 2020
Estimated completion	1 April 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

GSK1070806 — full drug profile →

Conditions studied

Behcet's Disease — all drugs for Behcet's Disease →

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with Behcet's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary outcome measure of the study is to demonstrate the safety and tolerability of GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease important secondary and exploratory outcomes.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis.
Fahey E, Doyle SL. · · 2019 · cited 215× · PMID 31293586 · DOI 10.3389/fimmu.2019.01426
The role of inflammasomes in human diseases and their potential as therapeutic targets.
Yao J, Sterling K, Wang Z, Zhang Y, et al · · 2024 · cited 135× · PMID 38177104 · DOI 10.1038/s41392-023-01687-y
Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics.
Marchesan JT, Girnary MS, Moss K, Monaghan ET, et al · · 2020 · cited 96× · PMID 31850638 · DOI 10.1111/prd.12269
Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases.
Park SY, Hisham Y, Shin HM, Yeom SC, et al · · 2022 · cited 19× · PMID 35885055 · DOI 10.3390/biomedicines10071750
The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases.
Turchin I, Bourcier M. · · 2022 · cited 18× · PMID 35997892 · DOI 10.1007/s12325-022-02241-y
Treatment Options in Pediatric Behçet's Disease.
Giani T, Luppino AF, Ferrara G. · · 2023 · cited 10× · PMID 36626047 · DOI 10.1007/s40272-022-00548-5
Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical Application.
Kim S, Yu H, Azam T, Dinarello CA. · · 2024 · cited 4× · PMID 38455460 · DOI 10.4110/in.2024.24.e1

Verify or expand the search:

Other trials of GSK1070806

Trials testing the same drug.

NCT06447506 — Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. · Phase 2 · terminated
NCT05999799 — A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Se · Phase 2 · terminated
NCT05590338 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intr · Phase 1 · completed
NCT04975438 — Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis · Phase 1 · completed
NCT03681067 — A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease · Phase 1, PHASE2 · completed

Other Cambridge University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03522662 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
Last refreshed: 11 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03522662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing